Neuroendocrine Pancreatic Tumors: Guidelines for Management and Update

@article{Burns2011NeuroendocrinePT,
  title={Neuroendocrine Pancreatic Tumors: Guidelines for Management and Update},
  author={William R. Burns and Barish H. Edil},
  journal={Current Treatment Options in Oncology},
  year={2011},
  volume={13},
  pages={24-34}
}
  • W. Burns, B. Edil
  • Published 1 March 2012
  • Medicine
  • Current Treatment Options in Oncology
Opinion statementPancreatic neuroendocrine tumors (PanNETs) are a diverse group of rare neoplasms. Commonly referred to as islet cell tumors, PanNETs are classified as functional or nonfunctional depending on their production of specific pancreatic endocrine hormones (e.g. insulin, gastrin, glucagon, and others) and association with the resultant clinical syndromes. While most PanNETs are sporadic, syndromic patients, in particular those with multiple endocrine neoplasia type 1 (MEN-1) and von… 
Neoplasms of the Neuroendocrine Pancreas: An Update in the Classification, Definition, and Molecular Genetic Advances
TLDR
Characteristic clinical and morphologic findings for certain functioning and syndromic panNENs should alert both pathologists and clinicians as appropriate patient management and possible genetic counseling may be necessary.
Pancreatic neuroendocrine tumors: Therapeutic challenges and research limitations
TLDR
The broad challenges associated with the management and the study of PNETs are discussed and modest improvements have been made over the past decades in the identification of potential oncogenic drivers in order to enhance the quality of life and increase survival for this growing population of patients.
Everolimus for the treatment of advanced pancreatic neuroendocrine tumors
TLDR
Everolimus appears to be promising for advanced pNETs and is usually tolerated with mainly mild adverse events, and future studies will establish whether everolimus, alone or in combination with other compounds, will also prove to be a valid treatment for inoperable tumors.
Advancements in pancreatic neuroendocrine tumors
TLDR
Novel molecular targeted therapies, such as everolimus and sunitinib, have recently come into the limelight and have shown significant promise for the treatment of locally advanced and metastatic disease.
Evaluation and management of pancreatic lesions in patients with von Hippel–Lindau disease
TLDR
The types of pancreatic lesions associated with VHL disease and their natural history are characterized, to identify particular lesions that necessitate treatment, and to define what forms of treatment should be undertaken.
Tumores neuroendocrinos del páncreas. Resultados quirúrgicos y sobrevida alejada
TLDR
The clinical characteristics, surgical outcomes and overall survival of patients with PNET who underwent resective surgery who underwent surgical resection from June 2005 to June 2012 were analyzed.
Nonfunctional pancreatic neuroendocrine tumors.
Role of Locoregional and Systemic Approaches for the Treatment of Patients with Metastatic Neuroendocrine Tumors
Although gastroenteropancreatic neuroendocrine tumors are often perceived as being indolent tumors, more than half of the patients will harbor liver metastases at the time of diagnosis.
Endocrine manifestations of von Hippel-Lindau disease.
TLDR
Pancreatic neuroendocrine proliferations, pheochromocytomas, and extra-adrenal paragangliomas are important endocrine manifestations of VHL disease and frequently display characteristic clinical, biochemical, and histopathologic features that can be helpful in suggesting V HL disease as the underlying etiology and distinguishing these tumors from sporadic cases.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 55 REFERENCES
Hereditary Pancreatic Endocrine Tumours
TLDR
The evidence is increasing that the life span of patients may be significantly improved with surgical intervention, mandating the widespread use of tumour surveillance and multidisciplinary team management.
Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survival.
TLDR
Age, grade, stage, and functional status predict survival in patients with PNETs, and survival has improved over time, but this is not explained by earlier diagnosis or stage migration.
TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system
TLDR
The tumor–node–metastasis proposal for foregut NETs of the stomach, duodenum, and pancreas that was designed, discussed, and consensually approved at this conference is reported.
Prognostic factors in pancreatic endocrine neoplasms: an analysis of 136 cases with a proposal for low-grade and intermediate-grade groups.
  • S. Hochwald, S. Zee, D. Klimstra
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2002
TLDR
Pancreatic endocrine neoplasms exhibit a spectrum of biologic behavior, and the proposed benign (macroadenoma) and borderline groups contain potentially aggressive tumors.
Update on the management of neuroendocrine hepatic metastases.
TLDR
The care of patients with NETs and hepatic metastases is reviewed, with emphasis on the increasingly important role of oncologic image-guided interventions.
Future directions in the treatment of neuroendocrine tumors: consensus report of the National Cancer Institute Neuroendocrine Tumor clinical trials planning meeting.
  • M. Kulke, L. Siu, James C Yao
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2011
TLDR
Key recommendations include the evaluation of pancreatic NET separately from NETs of other sites and the exclusion of patients with poorly differentiated histologies from trials focused on low-grade histologies.
A phase II study of capecitabine, oxaliplatin, and bevacizumab for metastatic or unresectable neuroendocrine tumors.
TLDR
A large number of patients with biopsy proven metastatic or unresectable neuroendocrine tumors received bevacizumab with or without capecitabine, and primary endpoints were progression free survival (PFS) and toxicity.
Concurrent resections of pancreatic islet cell cancers with synchronous hepatic metastases: outcomes of an aggressive approach.
TLDR
These data support aggressive concurrent resection of the pancreatic islet cell cancers and synchronic hepatic metastases when technically feasible and because disease progression is frequent and the major cause of death, investigations of adjunctive therapies are warranted.
Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms
TLDR
The anaplastic neuroendocrine tumor is strongly responsive to therapy with combined etoposide and cisplatin and should be evaluated for this possibility with appropriate immune staining or electron microscopy.
...
1
2
3
4
5
...